Retatrutide

Overview

Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.

Mechanism of action

Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation.

Key research findings

• Superior weight loss (24.2% at 48 weeks)
• Improved glycemic control (HbA1c reduction up to 2.16%)
• Enhanced cardiovascular benefits
• Hepatic fat reduction (up to 82%)
• Triple mechanism addresses obesity through multiple pathways

Research applications

Weight Loss

• Superior Weight Reduction — Clinical trials show 17.5% weight loss at 24 weeks and 24.2% at 48 weeks.
• Sustained Weight Management — Continuous weight loss with no plateau at 48 weeks suggests greater long-term potential.
• Triple Mechanism — Addresses obesity through appetite suppression, energy expenditure, and metabolic efficiency.

Type 2 Diabetes

• Superior Glycemic Control — HbA1c reductions up to 2.16% with 82% achieving target levels below 6.5%.
• Glucose-Dependent Regulation — Balanced glycemic control with minimal hypoglycemia risk.
• Insulin Sensitivity — Marked improvements in sensitivity with potential for reduced exogenous insulin requirements.

Cardiovascular/Metabolic

• Lipid Improvement — Non-HDL cholesterol reductions up to 26.9%, triglyceride reductions up to 40.6%.
• Blood Pressure Optimization — Consistent decreases in systolic and diastolic blood pressure across trials.
• Hepatic Fat Reduction — Up to 82% reduction in liver fat with normalization in 90% of participants.